Acta Medica ScandinavicaVolume 223, Issue 5 p. 385-387 Free Access Time for Reestablishment of Serum Lipid Lowering after Myocardial infarction? Ulf de Faire, Ulf de Faire Stockholm, SwedenSearch for more papers by this author Ulf de Faire, Ulf de Faire Stockholm, SwedenSearch for more papers by this author First published: January/December 1988 https://doi.org/10.1111/j.0954-6820.1988.tb15889.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1 Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405– 18. 2 Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. Acta Med Scand 1967; 181 (Suppl 466): 1– 92. 3 The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360– 81. 4 Carlson LA, Böttiger LE. Risk factors for ischaemic heart disease in men and women. Results of the 19-year follow-up of the Stockholm Prospective Study. Acta Med Scand 1985; 218: 207– 11. 5 Åberg H., Lithell H., Selinius I., Hedstrand H. Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris: results from a 10-year follow-up of Uppsala Primary Prevention Study. Atherosclerosis 1985; 54: 89– 97. 6 Lapidus L., Bengtsson C., Lindquist O., Sigurdsson JA, Rybo E. Triglycerides—main lipid risk factor for cardiovascular disease in women Acta Med Scand 1985; 217: 481– 9. 7 Nikkilä EA, Viikinkoski P., Valle M., Frick MH. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidemia. A 7 year prospective angiographic study. Br Med J 1984; 289: 220– 3. 8 Hamsten A., Wiman B., de Faire U., Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985; 313: 1557– 63. 9 Hamsten A., de Faire U., Walldius G. et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 1: 3– 9. 10 The Lipid Research Clinics' Coronary Primary Prevention Trial Results. JAMA 1984; 251: 351– 64, 365–74. 11 Levy RI, Brensike JF, Epstein SE et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 325– 37. 12 Strategies for the prevention of coronary heart disease; A policy statement of the European Atherosclerosis Society. Study Group, European Atherosclerosis Society. Eur Heart J 1987; 8: 77– 88. 13 Frick MH, Elo O., Haapa K. et al. Helsinki Heart Study: Primary-Prevention Trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317: 1237– 45. 14 Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986; 112: 432– 7. Volume223, Issue5January/December 1988Pages 385-387 ReferencesRelatedInformation

Time for Reestablishment of Serum Lipid Lowering after Myocardial infarction?

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info